Production of Antibodies Binding Murine Nuclear PD-L1
PD1/PD-L1 antibody therapy is used in the clinic (atezolizumab, avelumab, durvalumab), but its effect is ambiguous, both in patients and in mouse models. The purpose of this work was to analyze the binding of commercial and laboratory-obtained monoclonal antibodies to PD-L1. Previously, we obtained...
Saved in:
| Main Authors: | Valentina Kostenko, Alina Makarova, Elena Svirshchevskaya, Roman Kholodenko, Dmitry Ryazantsev, Ekaterina Ryabukhina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-04-01
|
| Series: | Proceedings |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2504-3900/103/1/24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01) -
Cell-based ELISpot protocol to detect and quantify antigen-specific antibody-secreting cells in murine whole-organ single-cell suspensions
by: Christina Brunner, et al.
Published: (2025-09-01) -
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01) -
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023-12-01) -
A Brief Chronicle of Antibody Research and Technological Advances
by: Kazutaka Araki, et al.
Published: (2024-11-01)